Redberg Rita F
Division of Cardiology at the University of California, San Francisco, USA.
Health Aff (Millwood). 2007 Jan-Feb;26(1):86-95. doi: 10.1377/hlthaff.26.1.86.
As the volume, complexity, and cost of new medical technology increase, the need for evaluating benefits and risks becomes increasingly important. Once the formal requirements for Food and Drug Administration approval and insurance coverage are met, however, few systematic criteria are applied to ensure patient benefit. A more systematic policy approach regarding new technologies is needed, with input from balanced groups reviewing evidence of clinical outcomes data to determine patient benefit. This paper examines cardiac computed tomography angiography as a case study; it proposes procedures designed to ensure that the benefits of new technologies justify their costs.
随着新型医疗技术的数量、复杂性和成本不断增加,评估其益处和风险的需求变得愈发重要。然而,一旦满足了美国食品药品监督管理局(FDA)批准和保险覆盖的正式要求,却很少有系统的标准用于确保患者能从中受益。需要一种关于新技术的更系统的政策方法,由各平衡团体提供意见,审查临床结果数据的证据以确定患者是否能受益。本文以心脏计算机断层扫描血管造影为例进行研究;提出了旨在确保新技术的益处能证明其成本合理性的程序。